SOLENO THERAPEUTICS INC

NASDAQ: SLNO (Soleno Therapeutics, Inc.)

Last update: yesterday, 6:41PM

67.48

-4.68 (-6.49%)

  • 1D -6.49%
  • 5D -2.10%
  • 1M -3.94%
  • 6M 30.27%
  • YTD 47.63%
  • 1Y 49.26%
  • 5Y 35.91%
Previous Close 72.16
Open 71.39
Volume 1,270,316
Avg. Volume (3M) 969,614
Market Cap 3,094,450,688
Price / Book 14.92
52 Weeks Range
36.61 (-45%) — 74.00 (9%)
Earnings Date 7 May 2025 - 12 May 2025
Diluted EPS (TTM) -4.38
Total Debt/Equity (MRQ) 21.55%
Current Ratio (MRQ) 15.68
Operating Cash Flow (TTM) -69.10 M
Levered Free Cash Flow (TTM) -7.47 M
Return on Assets (TTM) -45.06%
Return on Equity (TTM) -87.35%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Bearish Bearish
Biotechnology (Global) Bearish Bearish
Stock Soleno Therapeutics, Inc. Bearish Bullish

AIStockmoo Score

-1.3
Analyst Consensus 3.0
Insider Activity NA
Price Volatility -3.0
Technical Moving Averages -5.0
Technical Oscillators 0.0
Average -1.25

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
SLNO 3 B - - 14.92
KRYS 5 B - 62.59 5.11
TGTX 5 B - 133.40 26.86
ADMA 5 B - 23.67 15.26
SRPT 4 B - - 3.13
RYTM 3 B - - 190.80

Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.
Sector Healthcare
Industry Biotechnology
Investment Style Small Growth
% Held by Insiders 2.40%
% Held by Institutions 103.27%

Ownership

Name Date Shares Held
Vivo Capital, Llc 31 Mar 2025 4,458,294
Nantahala Capital Management, Llc 31 Dec 2024 3,928,966
Adage Capital Partners Gp, L.L.C. 31 Dec 2024 2,775,976
Commodore Capital Lp 31 Dec 2024 1,525,000
Perceptive Advisors Llc 31 Dec 2024 1,501,040
Westfield Capital Management Co Lp 31 Mar 2025 1,211,245
Vestal Point Capital, Lp 31 Dec 2024 1,060,000
52 Weeks Range
36.61 (-45%) — 74.00 (9%)
Price Target Range
97.00 (43%) — 145.00 (114%)
High 145.00 (Piper Sandler, 114.88%) Buy
Median 105.00 (55.60%)
Low 97.00 (Guggenheim, 43.75%) Buy
Average 111.86 (65.77%)
Total 7 Buy
Avg. Price @ Call 50.18
Firm Date Target Price Call Price @ Call
Baird 08 May 2025 105.00 (55.60%) Buy 0.000
27 Mar 2025 102.00 (51.16%) Buy 67.39
Guggenheim 08 May 2025 97.00 (43.75%) Buy 0.000
28 Mar 2025 81.00 (20.04%) Buy 71.99
Piper Sandler 24 Apr 2025 145.00 (114.88%) Buy 74.23
HC Wainwright & Co. 15 Apr 2025 100.00 (48.19%) Buy 70.25
31 Mar 2025 100.00 (48.19%) Buy 71.45
Stifel 28 Mar 2025 108.00 (60.05%) Buy 71.99
05 Mar 2025 74.00 (9.66%) Buy 44.99
Cantor Fitzgerald 27 Mar 2025 123.00 (82.28%) Buy 67.39
Laidlaw & Co. 27 Mar 2025 105.00 (55.60%) Buy 67.39
Show more

No data within this time range.

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria